Vertex's tezacaftor shows positive outcome in two Phase III trials to treat CF

US-based biotechnology firm Vertex Pharmaceuticals has reported a positive outcome from two Phase III clinical trials of tezacaftor (VX-661) in combination with ivacaftor to treat cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news